| |
| |
|
| Insider
Information: |
Stahl Neil |
| Relationship: |
EVP Research and Devel... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
50,999 |
|
|
Indirect Shares
|
10,439 |
|
|
| Direct
Value |
$49,290,024 |
|
|
|
Indirect Value
|
$10,089,189 |
|
|
| Total
Shares |
61,438 |
|
|
| Total
Value |
$59,379,213 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 57.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regeneron Pharmaceuticals Inc |
REGN |
EVP Research and Devel... |
2024-02-26 |
50,999 |
2024-02-26 |
10,439 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
140 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-02-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
335 |
52,795 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-11-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
330 |
52,465 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-11-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
400 |
52,700 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2024-02-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,020 |
50,999 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2006-02-03 |
4 |
OE |
$7.41 |
$296,400 |
D/D |
40,000 |
27,127 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Therap & Clin Prog Dev |
• – – |
2006-10-31 |
4 |
OE |
$9.50 |
$623,150 |
D/D |
60,000 |
19,647 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2007-04-20 |
4 |
OE |
$8.77 |
$219,250 |
D/D |
25,000 |
29,297 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2008-09-29 |
4 |
OE |
$8.77 |
$219,250 |
D/D |
25,000 |
25,350 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2009-07-24 |
4 |
OE |
$9.49 |
$949,000 |
D/D |
100,000 |
89,813 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2011-03-30 |
4 |
OE |
$13.00 |
$99,996 |
D/D |
7,692 |
58,042 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2011-04-04 |
4 |
OE |
$13.00 |
$1,200,004 |
D/D |
92,308 |
142,658 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2011-09-06 |
4 |
OE |
$11.64 |
$964,002 |
D/D |
82,818 |
133,168 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-02-13 |
4 |
OE |
$8.50 |
$566,661 |
D/D |
66,666 |
92,177 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-02-14 |
4 |
OE |
$16.80 |
$840,000 |
D/D |
50,000 |
140,323 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res & Dev Sciences |
• – – |
2012-06-18 |
4 |
OE |
$20.32 |
$1,932,005 |
D/D |
95,079 |
154,200 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-08-28 |
4 |
OE |
$21.92 |
$876,800 |
D/D |
40,000 |
99,121 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-11-20 |
4 |
OE |
$16.80 |
$915,600 |
D/D |
54,500 |
104,219 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-11-30 |
4 |
OE |
$20.32 |
$199,994 |
D/D |
9,483 |
51,422 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-12-17 |
4 |
OE |
$16.80 |
$99,994 |
D/D |
5,952 |
48,988 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2013-05-10 |
4 |
OE |
$21.92 |
$1,215,201 |
D/D |
55,438 |
104,426 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2013-12-18 |
4 |
OE |
$21.25 |
$99,981 |
D/D |
4,705 |
24,391 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-02-12 |
4 |
OE |
$16.80 |
$1,094,406 |
D/D |
54,548 |
50,807 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-08-06 |
4 |
OE |
$21.25 |
$743,750 |
D/D |
35,000 |
48,527 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-11-18 |
4 |
OE |
$115.29 |
$1,931,915 |
D/D |
16,757 |
30,284 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-12-16 |
4 |
OE |
$30.63 |
$99,976 |
D/D |
3,264 |
6,541 |
0 |
- |
|
140 Records found
|
|
Page 4 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
